Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Non-Muscle Invasive Bladder Neoplasms 5Carcinoma in Situ 3Urologic Neoplasms 2Urinary Bladder Neoplasms 2Carcinoma, Transitional Cell 2

Interventions

valrubicin 3dodecyl maltoside 3Mitomycin 3Magnetic Resonance Imaging 3Gemcitabine 3durvalumab 2Interferon beta-1b 2Electrocardiography 2Diphenhydramine 2Cystoscopy 2Biopsy 2Acetaminophen 2toripalimab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1enfortumab vedotin 1cemiplimab 1apaziquone 1aldesleukin 1advexin 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Standard of Care 1Sampling Studies 1Respiratory Function Tests 1Proflavine 1Prochlorperazine 1Positron-Emission Tomography 1Physical Examination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma in Situ × dodecyl maltoside × Clear all
NCT07283835 2026-04-23

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Lepu Biopharma Co., Ltd.

Phase 2 Recruiting
16 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT04452591 2026-03-16

BOND-003

CG Oncology, Inc.

Phase 3 Active not recruiting
190 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT04387461 2024-09-25

CORE-001

CG Oncology, Inc.

Phase 2 Completed
35 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡